MGMT and neoplasm: In Cox adjusted analysis for all prognostic factors, age 60–69 years (HR1.51, 95% CI [1.19–1.92], p = 0.001) or ≥70 years (HR2.39, 95% CI [1.86–3.06], p<0.001), unmethylated MGMT promoter (HR2.09, 95% CI [1.66–2.63], P<0.001), right tumour location (HR1.40, 95% CI [1.13–1.74], p = 0.002), midline or bilateral tumour location (HR1.70, 95% CI [1.14–2.55], compared to left tumour location, p = 0.010) and multifocality (HR1.57, 95% CI [1.04–2.37], p = 0.034, Fig 2E) were all independently associated with poor prognosis.